SCHEMBL19505418

SCHEMBL19505418

CCOc1nc2c(n1Cc1ccccc1)C(=O)N(CCCO)C(O)N2CC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE5A O76074 11/20 0.42
▸ ADORA3 P0DMS8 3/20 0.38
▸ P2RX3 P56373 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ TSHR P16473 1/20 0.34
▸ ABCB11 O95342 1/20 0.34
▸ EGFR P00533 1/20 0.34
▸ ERBB2 P04626 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ ADRB3 P13945 1/20 0.34
▸ ADRA2B P18089 1/20 0.34
▸ SLC6A2 P23975 1/20 0.34
▸ TBXAS1 P24557 1/20 0.34
▸ HTR2C P28335 1/20 0.34
▸ AGTR1 P30556 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ HTR2B P41595 1/20 0.34
▸ AGTR2 P50052 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21499684 0.91 P2RX3 (0.44) PDE5AP2RX3
SCHEMBL21499650 0.89 PDE5A (0.41) PDE5AADORA3P2RX3MEN1KMT2A
SCHEMBL19505233 0.85 P2RX3 (0.45) PDE5AP2RX3
SCHEMBL19375680 0.84 TRPC4 (0.46) PDE5AADORA3P2RX3
SCHEMBL19374881 0.83 P2RX3 (0.44) PDE5AP2RX3
SCHEMBL18834873 0.82 PDE5A (0.39) PDE5AP2RX3TSHR
SCHEMBL19375611 0.81 TRPC4 (0.41) PDE5AADORA3P2RX3ALDH1A1
SCHEMBL20432442 0.79 TRPC5 (0.48) ADORA3P2RX3
SCHEMBL18835145 0.79 ADORA3 (0.36) PDE5AADORA3MEN1KMT2ATSHR
SCHEMBL22105553 0.79 ADORA3 (0.40) PDE5AADORA3MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9969736-B2 Substituted xanthines and methods of use thereof HYDRA BIOSCIENCES, INC. (US) 2018-05-15 — — US disclosed
US-20170305910-A1 Substituted Xanthines and Methods of Use Thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-10-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305910-A1 Substituted Xanthines and Methods of Use Thereof TRPC5, TRPC7, TRPC4 PDE5A 461/4885ADORA3 449/4885P2RX3 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback